MedTrace Logo

BIG Molecular Screening Feasibility Study

NCT02094742 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-10-15

No results posted yet for this study

Summary

This pilot study examines the feasibility and turnaround time of performing and obtaining data from a few key molecular assays. These assays will be performed using different laboratories and technologies from core biopsies taken from patients diagnosed with invasive recurrent or metastatic breast cancer. All results will be uploaded, stored and assessed using the IT Molecular Screening Prototype Platform (MSPP). The MSPP will also be evaluated for ease of use to screen patients for participation in future molecularly defined clinical trials in breast cancer.

Conditions

Interventions

PROCEDURE

biopsy

Sponsors & Collaborators

  • Breast International Group

    collaborator OTHER

  • Jules Bordet Institute

    lead OTHER

Principal Investigators

  • Sherene Loi, MD, PhD · Institut Jules Bordet, Brussels, Belgium

  • Christos Sotiriou, MD, PhD · Institut Jules Bordet, Brussels, Belgium

  • Martine Piccart, MD, PhD · Institut Jules Bordet, Brussels, Belgium

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • Belgium
  • Germany
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02094742 on ClinicalTrials.gov